Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Sarcoma 4Head & Neck 4CNS 4Other hematologic neoplasm 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Valganciclovir × Gastrointestinal × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡